decline of cognitive function
Conditions
Interventions
Longvida 400mg/day, 12weeks
Placebo, 12weeks
Sponsors
HUMA R&D Co.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Subjects aged from 50 to 79 years old 2)Japanese male and female 3)Having cognitive complaints 4)Nonsmoker 5)HDS-R score more than 16 points at screening test
Exclusion criteria
Exclusion criteria: 1)Patients under medical treatment 2)Patients under dietetic treatment or ergotherapy 3)Subjects who have previous medical history and/or current medical history of serious diseases (e.g., liver, kidney, endocrine, cardiovascular system, digestive organ, lung, blood, and/or metabolism). 4)Subjects who have undergone gastrointestinal tract surgery; except appendectomy. 5)Subjects who have previous medical history and/or current medical history of mental disorder. 6)Subjects who have previous medical history of drug and/or food allergy. 7)Subjects who have previous medical history and/or current medical history of drug dependence and/or drug abuse. 8)Subjects who participate in other clinical trial within a month 9)Subjects who work time is irregular. 10)Subjects who have previous medical history and/or current medical history of alcoholism 11)Subjects who are in receipt of public assistance 12) Subjects who have been determined ineligible by principal investigator or sub-investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Repeatable Battery for the Assessment of Neuropsychological Status Hasegawa dementia rating scale | — |
Secondary
| Measure | Time frame |
|---|---|
| Subjective symptoms: intake 0, 2, 4, 6, 8, 10, 12 weeks Safety(blood test, history taking):intake 0, 12 weeks | — |
Countries
Japan
Contacts
Public ContactSatomi Iwata
Omnica Co.,Ltd Research team
Outcome results
None listed